Emerging Therapeutic Approaches to Target BRAF Mutations in Solid Tumors | Supplements And Featured Publications

The Emerging Therapeutic Approaches to Target BRAF Mutations in Solid Tumors publication covers some of the latest practice-changing advances as it relates to novel treatment strategies for patients with BRAF-mutated solid tumors.

KIN-2787 Looks to Fill Unmet Need in Class II/III BRAF-Altered Solid Tumors

February 22, 2022

Investigators hope to address the need for additional treatment options for patients with class II or class III BRAF-altered disease with KIN-2787, a next-generation, orally available, potent, and selective small molecule inhibitor.

Personalized Medicine Approaches Continue to Gain Steam in BRAF/NRAS+ Metastatic Melanoma

February 09, 2022

Meredith McKean, MD, MPH, discusses how the presence of atypical BRAF mutations affects treatment selection in patients with metastatic melanoma, highlighted the ongoing KN-8701 trial, and explained why developments in this space further solidify the importance of broad molecular profiling.